Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-2.61% $0.602
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 5.20 mill |
EPS: | 1.770 |
P/E: | 0.340 |
Earnings Date: | Mar 27, 2024 |
SharesOutstanding: | 8.65 mill |
Avg Daily Volume: | 0.488 mill |
RATING 2024-03-28 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | n/a | |||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 0.340 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.06x |
Company: PE 0.340 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.538 - 0.666 ( +/- 10.64%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-16 | Miller Josh | Sell | 46 | Common Stock |
2024-02-29 | Dgp Co., Ltd. | Sell | 3 400 000 | Common Stock |
2023-11-16 | Miller Josh | Sell | 38 | Common Stock |
2023-09-26 | Eom Minhee | Buy | 0 | |
2023-08-21 | Ko Hyuk Joon | Buy | 0 |
INSIDER POWER |
---|
-60.84 |
Last 81 transactions |
Buy: 16 542 799 | Sell: 13 981 621 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.602 (-2.61% ) |
Volume | 0.0336 mill |
Avg. Vol. | 0.488 mill |
% of Avg. Vol | 6.88 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.